Clinicopathological response to neoadjuvant therapies and pathological complete response as a biomarker of survival in human epidermal growth factor receptor-2 enriched breast cancer – A retrospective cohort study

BACKGROUND: Human epidermal growth factor receptor-2 (HER2) is overexpressed in 20–25% of breast cancers. Complete eradication of disease following neoadjuvant therapies and chemotherapy has been referred to as pathological complete response (pCR). AIMS: To determine clinicopathological predictors o...

Descripción completa

Detalles Bibliográficos
Autores principales: Davey, Matthew G., Kerin, Eoin, O'Flaherty, C., Maher, Elizabeth, Richard, Vinitha, McAnena, Peter, McLaughlin, Ray P., Sweeney, Karl J., Barry, Michael K., Malone, Carmel M., Wyns, William, Soliman, Osama, Miller, Nicola, Keane, Maccon M., Lowery, Aoife J., Kerin, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234352/
https://www.ncbi.nlm.nih.gov/pubmed/34171619
http://dx.doi.org/10.1016/j.breast.2021.06.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234352/
https://www.ncbi.nlm.nih.gov/pubmed/34171619
http://dx.doi.org/10.1016/j.breast.2021.06.005

Ejemplares similares